Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle ...
Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ...
Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies ...
First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity Pilatu ...
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing ...
Soligenix Announces HyBryte™ Clinical Summary Published in “Expert Opinion on Investigational Drugs”
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
ImmunityBio has achieved a significant milestone beyond its already approved drug, ANKTIVA. On March 13, 2026, the biotechnology firm announced the successful validation of a scalable manufacturing ...
Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3- plus RAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results